Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Analysis Receives CE Mark for Microbiome Test on Luminex Magpix Instrument

NEW YORK – Microbiome diagnostic company Genetic Analysis said on Tuesday it has received CE marking for the GA-map Dysbiosis test for use on the Luminex Magpix instrument.

Oslo, Norway-based Genetic Analysis said launching the test kit on the Luminex platform provides access to the large number of labs that have already installed the Magpix and will increase the addressable market for the GA-map Dysbiosis test.

"This not only further strengthens our commercial reach and enables GA to capitalize on all labs that already have the Magpix system installed, but also give us an opportunity to offer a less costly option for customers that install the system for GA-map testing only," Genetic Analysis CEO Ronny Hermansen said in a statement.

"The addition of the CE-marked GA-map Dysbiosis Test kit will enable our Magpix customers to add microbiome testing to their current test portfolio," added Christoph Cordes, VP of Luminex's licensed technology group.

Luminex was acquired by DiaSorin last April.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.